[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse NAMPT

Summary
SymbolNAMPT
Namenicotinamide phosphoribosyltransferase
Aliases visfatin; PBEF1; pre-B-cell colony enhancing factor 1; 1110035O14Rik; VF; NAmPRTase; pre-B cell-enhancing fa ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Secreted Note=Under non-inflammatory conditions, visfatin predominantly exhibits a granular pattern within the nucleus. Secreted by endothelial cells upon IL-1beta stimulation. Abundantly secreted in milk, reaching 100-fold higher concentrations compared to maternal serum.
Domain PF04095 Nicotinate phosphoribosyltransferase (NAPRTase) family
Function

Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway. The secreted form behaves both as a cytokine with immunomodulating properties and an adipokine with anti-diabetic properties, it has no enzymatic activity, partly because of lack of activation by ATP, which has a low level in extracellular space and plasma. Plays a role in the modulation of circadian clock function. NAMPT-dependent oscillatory production of NAD regulates oscillation of clock target gene expression by releasing the core clock component: CLOCK-ARNTL/BMAL1 heterodimer from NAD-dependent SIRT1-mediated suppression (By similarity).

> Gene Ontology
 
Biological Process GO:0006732 coenzyme metabolic process
GO:0006733 oxidoreduction coenzyme metabolic process
GO:0006766 vitamin metabolic process
GO:0006767 water-soluble vitamin metabolic process
GO:0006769 nicotinamide metabolic process
GO:0007565 female pregnancy
GO:0007623 circadian rhythm
GO:0009108 coenzyme biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009435 NAD biosynthetic process
GO:0009820 alkaloid metabolic process
GO:0019359 nicotinamide nucleotide biosynthetic process
GO:0019362 pyridine nucleotide metabolic process
GO:0019363 pyridine nucleotide biosynthetic process
GO:0019674 NAD metabolic process
GO:0032922 circadian regulation of gene expression
GO:0033002 muscle cell proliferation
GO:0044706 multi-multicellular organism process
GO:0046496 nicotinamide nucleotide metabolic process
GO:0048511 rhythmic process
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0051186 cofactor metabolic process
GO:0051188 cofactor biosynthetic process
GO:0051767 nitric-oxide synthase biosynthetic process
GO:0051769 regulation of nitric-oxide synthase biosynthetic process
GO:0051770 positive regulation of nitric-oxide synthase biosynthetic process
GO:0072524 pyridine-containing compound metabolic process
GO:0072525 pyridine-containing compound biosynthetic process
GO:1901293 nucleoside phosphate biosynthetic process
Molecular Function GO:0004514 nicotinate-nucleotide diphosphorylase (carboxylating) activity
GO:0005125 cytokine activity
GO:0008144 drug binding
GO:0016757 transferase activity, transferring glycosyl groups
GO:0016763 transferase activity, transferring pentosyl groups
GO:0047280 nicotinamide phosphoribosyltransferase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04621 NOD-like receptor signaling pathway
hsa00760 Nicotinate and nicotinamide metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1368108: BMAL1
R-HSA-400253: Circadian Clock
R-HSA-1430728: Metabolism
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-196849: Metabolism of water-soluble vitamins and cofactors
R-HSA-197264: Nicotinamide salvaging
R-HSA-196807: Nicotinate metabolism
Summary
SymbolNAMPT
Namenicotinamide phosphoribosyltransferase
Aliases visfatin; PBEF1; pre-B-cell colony enhancing factor 1; 1110035O14Rik; VF; NAmPRTase; pre-B cell-enhancing fa ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NAMPT and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between NAMPT and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29721178Metastatic MelanomaInhibit immunity; Resistant to immunotherapyFurthermore, cells that become resistant to BRAF inhibitors (BiR) show a significant increase of eNAMPT levels. Lastly, high eNAMPT levels correlate with a significantly shorter overall survival. Our findings suggest that eNAMPT is a novel marker of tumor burden and response to therapy in patients with metastatic melanoma carrying BRAF mutations.
Summary
SymbolNAMPT
Namenicotinamide phosphoribosyltransferase
Aliases visfatin; PBEF1; pre-B-cell colony enhancing factor 1; 1110035O14Rik; VF; NAmPRTase; pre-B cell-enhancing fa ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NAMPT in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.87; FDR: 0.04170 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolNAMPT
Namenicotinamide phosphoribosyltransferase
Aliases visfatin; PBEF1; pre-B-cell colony enhancing factor 1; 1110035O14Rik; VF; NAmPRTase; pre-B cell-enhancing fa ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NAMPT in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.530.137
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3480.903
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6780.716
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5080.342
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.3770.543
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5960.847
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0940.87
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2690.909
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5080.845
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0610.972
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2170.937
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.110.372
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolNAMPT
Namenicotinamide phosphoribosyltransferase
Aliases visfatin; PBEF1; pre-B-cell colony enhancing factor 1; 1110035O14Rik; VF; NAmPRTase; pre-B cell-enhancing fa ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NAMPT. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNAMPT
Namenicotinamide phosphoribosyltransferase
Aliases visfatin; PBEF1; pre-B-cell colony enhancing factor 1; 1110035O14Rik; VF; NAmPRTase; pre-B cell-enhancing fa ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NAMPT. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NAMPT.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNAMPT
Namenicotinamide phosphoribosyltransferase
Aliases visfatin; PBEF1; pre-B-cell colony enhancing factor 1; 1110035O14Rik; VF; NAmPRTase; pre-B cell-enhancing fa ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NAMPT. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNAMPT
Namenicotinamide phosphoribosyltransferase
Aliases visfatin; PBEF1; pre-B-cell colony enhancing factor 1; 1110035O14Rik; VF; NAmPRTase; pre-B cell-enhancing fa ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NAMPT expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNAMPT
Namenicotinamide phosphoribosyltransferase
Aliases visfatin; PBEF1; pre-B-cell colony enhancing factor 1; 1110035O14Rik; VF; NAmPRTase; pre-B cell-enhancing fa ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NAMPT and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNAMPT
Namenicotinamide phosphoribosyltransferase
Aliases visfatin; PBEF1; pre-B-cell colony enhancing factor 1; 1110035O14Rik; VF; NAmPRTase; pre-B cell-enhancing fa ......
Chromosomal Location7q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NAMPT collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting NAMPT.
ID Name Drug Type Targets #Targets
DB05217GMX1777Small MoleculeNAMPT1
DB12731DaporinadSmall MoleculeNAMPT1